SCHEMBL2492827

SCHEMBL2492827

O=C(O)c1cc(NC(=O)C2CCCCC2)ccc1Cl

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.56
PTPN1 P18031 1/20 0.56
GRM4 Q14833 1/20 0.56
ALDH1A1 P00352 3/20 0.55
TSHR P16473 1/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
LMNA P02545 1/20 0.54
ALOX15 P16050 1/20 0.54
ALOX12 P18054 1/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPC1 O15118 2/20 0.53
KDM4E B2RXH2 3/20 0.53
POLB P06746 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
MAPT P10636 1/20 0.53
RAB9A P51151 1/20 0.53
KCNK3 O14649 1/20 0.52
KCNK9 Q9NPC2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8278410 0.87 ALDH1A1 (0.60) HPGDPTPN1GRM4ALDH1A1TSHR
SCHEMBL1749152 0.87 HPGD (0.58) HPGDPTPN1GRM4ALDH1A1TSHR
SCHEMBL11594912 0.87 HPGD (0.61) HPGDPTPN1ALDH1A1NPC1KDM4E
SCHEMBL2239611 0.85 HPGD (0.64) HPGDPTPN1GRM4ALDH1A1TSHR
SCHEMBL1516160 0.84 HPGD (0.58) HPGDPTPN1ALDH1A1NPC1KDM4E
SCHEMBL4096062 0.81 PTPN1 (0.58) HPGDPTPN1GRM4ALDH1A1TSHR
SCHEMBL2241850 0.81 ALDH1A1 (0.60) HPGDPTPN1ALDH1A1TSHRMEN1
SCHEMBL11729871 0.79 HPGD (0.55) HPGDPTPN1ALDH1A1MEN1KMT2A
SCHEMBL2344329 0.79 PTPN1 (0.56) HPGDPTPN1ALDH1A1TSHRMEN1
SCHEMBL1749832 0.78 HPGD (0.54) HPGDPTPN1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 HPGD 3487/4885PTPN1 84/4885GRM4 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.